Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AX-8 Pharmacokinetics and Safety in Healthy Volunteers
NCT04107441Phase 1Completed
- Sponsor
- Axalbion Therapeutics Limited
- Start
- Sep 2019
- Primary completion
- Feb 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of ax-8 in chronic cough (2 arms), sponsored by Axalbion Therapeutics Limited. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) at 44 days, Changes in biochemistry parameters - Total protein at 44 days and 44 more. Started Sep 2019; status: completed.
02
Drugs
ax-8
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT04107441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04107441.